Cardiovascular outcome trials have demonstrated significant reductions in major adverse cardiovascular events with certain agents in this class (liraglutide, injectable semaglutide, and dulaglutide), leading to expanded indications for cardiovascular risk reduction
More recently, researchers discovered, almost by accident, that these same drugs could also drive significant weight loss
Physicians should screen for conditions like depression before prescribing the drugs, the researchers said
10.1016/j.phrs.2009.06.004 140
This data helps identify patterns and optimize your personal approach
Muscle injection causes faster, more variable absorption and increased injection site pain